Last reviewed · How we verify
HD-TIV
HD-TIV is a high-dose trivalent inactivated influenza vaccine designed to provide enhanced immune protection against three influenza virus strains.
HD-TIV is a high-dose trivalent inactivated influenza vaccine designed to provide enhanced immune protection against three influenza virus strains. Used for Seasonal influenza prevention in adults aged 65 years and older, Seasonal influenza prevention in immunocompromised adults.
At a glance
| Generic name | HD-TIV |
|---|---|
| Sponsor | McGill University Health Centre/Research Institute of the McGill University Health Centre |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology/Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
HD-TIV contains four times the standard antigen dose (60 μg per strain versus 15 μg in standard-dose vaccines) to elicit a stronger humoral and cellular immune response. This higher antigen load is intended to improve immunogenicity and protective efficacy, particularly in older adults and immunocompromised populations who may have diminished responses to conventional-dose influenza vaccines.
Approved indications
- Seasonal influenza prevention in adults aged 65 years and older
- Seasonal influenza prevention in immunocompromised adults
Common side effects
- Injection site soreness
- Myalgia
- Fatigue
- Headache
Key clinical trials
- Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) (PHASE1)
- A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone® HD Vaccine (PHASE1)
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine (PHASE1, PHASE2)
- A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults (PHASE2)
- High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients (PHASE2)
- Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age (PHASE3)
- Open-Label Influenza Vaccine Evaluation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: